# OnCo record nct03260894 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03260894/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03260894", "NCT03260894" ;
  schema:name "Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)"@en ;
  schema:description "A phase 3 trial of Pembrolizumab, Epacadostat, Sunitinib and Pazopanib in Renal cell carcinoma, run by Incyte Corporation, completed."@en ;
  schema:url <https://onco.cc/trials/nct03260894/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03260894> ;
  onco:status "completed" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/rcc/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/epacadostat/>, <https://onco.cc/drugs/sunitinib/>, <https://onco.cc/drugs/pazopanib/> ;
  onco:companies <https://onco.cc/companies/incyte/> .